Drug Trial Radar · NCT02047994
Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality
Last checked: Nov 19, 2026Latest source record: May 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30,000
Planned (sponsor's estimate)
Start
Mar 2013
Primary completion
Dec 2033
Study completion Dec 2035
Sponsor
- Lead sponsor
- International Agency for Research on CancerAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Latvia; Technion, Israel Institute of Technology; Karolinska Institutet; Academic Histology Laboratory (Latvia); Vanderbilt University
- First posted
- Jan 29, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 40 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Currently no ideal preventive modalities are available for reducing gastric-cancer caused mortality in organized population-based application. The primary objective of the study is to determine if H.pylori screening followed by eradication of positive subjects and endoscopic follow-up of those with serological evidence of atrophic gastritis reduces mortality from gastric cancer in middle-aged people in high-risk areas. The GISTAR study is a multicenter randomized study of H.pylori eradication and pepsinogen testing for prevention of gastric cancer mortality. Altogether 30.000 individuals aged 40-64 years will be enrolled, providing 90% study power to detect at least 35% reduction in gastric cancer mortality at 15 years of follow-up. Participants will be randomly allocated to one of two groups. In the active investigation/management group those positive for H.pylori will be offered eradication therapy and individuals with decreased pepsinogen I/II ratio will be invited for endoscopy. The control group will receive standard health care. The primary endpoint for this trial will be the mortality difference from gastric cancer between the two groups at 15 years or when enough cases accumulate to demonstrate a statistical difference. The study is expected to provide valuable information on the utility for reduction in gastric cancer mortality of: 1) H.pylori eradication in adults on a population-basis, including subjects who may already have pre-malignant lesions; and 2) pepsinogen testing in screening settings. A pilot study of 3,455 individuals prior to the main trial was conducted from October 2013 to December 2016.
Conditions
- Helicobacter Pylori Infections
- Atrophic Gastritis
- Gastric Cancer
Interventions
Triple therapyDrug
Participants who are positive with Helicobacter pylori in Group1 will receive triple therapy. * Esomeprazole 40 mg bid for 10 days * Clarithromycin 500 mg bid for 10 days * Amoxicillin 1000 mg bid for 10 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Gastric cancer mortalityTime frame: 15 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Clinical and Preventive Medicine, University of Latvia
Riga, Latvia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.